FDA approves Genzyme pediatric leukemia drug

12/30/2004 | Wall Street Journal, The

The FDA approved Genzyme's leukemia drug, Clolar, assigning orphan status to the drug developed for treating patients age 21 and younger who do not respond to chemotherapy. Genzyme expects the drug to be available in January, at an estimated price of $34,000 per dose. One expert said it is likely the drug also will be used off-label in combination with other treatments for adult patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC